CHCWM – Cancer & Hematology Centers of West Michigan

ALKS 4230-003 (Alkermes Inc. )

ALKS 4230-003 (Alkermes Inc. )

Description:  Clinical and Immunologic Activity of Nemvaleukin Alfa With a less Frequent IV Dosing With Pembrolizumab and Impact on Tumor Microenvironment in Soloid Tumor Patients (Artistry-3)

Mechanism of ActionIL2 receptor agonist

Target Patient Population: Cutaneous melanoma, Renal Cell, Triple Negative Breast, MMS Colorectal, Ovarian and any MSI-High solid tumors

Study Design: Study drug is administered IV every 3 weeks